The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Outcomes of patients with DLBCL who relapse early following R-ICE chemoimmunotherapy
Paolo Caimi, MD, Cleveland Clinic, Cleveland, OH, shares insights into the results of a study investigating the characteristics and outcomes of relapsed/refractory (R/R) patients with diffuse large B-cell lymphoma (DLBCL) achieving complete remission (CR) after treatment with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) chemoimmunotherapy. The study showed that whilst the majority of patients who relapsed early following R-ICE had poor outcomes, a minority of patients remained chemosensitive and were able to achieve long-term disease control, in particular if they proceeded to autologous transplantation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Membership on an entity’s Board of Directors or advisory committees; Genmab: Membership on an entity’s Board of Directors or advisory committees; Genentech: Membership on an entity’s Board of Directors or advisory committees; Takeda: Membership on an entity’s Board of Directors or advisory committees; MEI Pharma: Membership on an entity’s Board of Directors or advisory committees; ADC Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Kite Pharma: Membership on an entity’s Board of Directors or advisory committees.
